Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Repotrectinib with Voriconazole or Quinidine in Healthy Participants
NCT06493409Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of repotrectinib in non-small cell lung cancer (NSCLC) and solid tumor (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration and 1 more. Started Aug 2024; status: completed.
02
Drugs
repotrectinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT06493409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06493409.